Mixed results with positive revenue growth (11.5% quarterly, 20.9% YTD) and strong domestic sales momentum (27.7%), but offset by significant gross margin contraction (43.7% to 33.9%), international sales decline (-38.9%), and manufacturing cost pressures. Stock declined 8.8% post-earnings. Positive outlook includes capacity expansion and market share gains, but execution risks remain around contamination, competition, and yield improvements.
Immucell news
$9.97+0.86%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Immucell
Zacks Investment ResearchAug 27, 10:10 AM ETNeutral
Also mentions ICCC
Articles that tag ICCC but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology